Verona Pharma Plc
(NASDAQ : VRNA)

( )
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Yes, 3x ETFs are Awesome!
Like TNA, UGAZ, UWTI, NUGT? We do too...Join Up!
100% secure: your email is never shared, and you may opt out at any time.
...
Health Technology » Pharmaceuticals Other
symbolcompany%chnglast%shortavg$volume
HZNPHorizon Therapeutics Plc 24.45%76.906.5%$150.39m
VRXValeant Pharmaceuticals International, Inc. 1.84%19.3414.1%$113.80m
CTLTCatalent, Inc. 1.60%89.592.1%$94.48m
JAZZJazz Pharmaceuticals Plc 10.99%122.622.4%$64.98m
BHCBausch Health Cos., Inc. 1.84%19.340.0%$64.75m
TNXPTonix Pharmaceuticals Holding Corp. 5.79%1.283.9%$63.68m
ARGXargenx SE 0.33%232.380.0%$46.77m
PCRXPacira Biosciences, Inc. 2.24%56.5210.3%$44.88m
ICLRICON plc 1.58%190.034.3%$42.49m
UTHRUnited Therapeutics Corp. -0.73%113.2614.1%$42.17m
ICPTIntercept Pharmaceuticals, Inc. 0.72%47.9216.8%$41.75m
PRGOPerrigo Co. Plc -5.06%52.336.8%$40.16m
GWPHGW Pharmaceuticals Plc -0.41%134.816.2%$38.00m
MYOKMyoKardia, Inc. 2.49%100.441.8%$36.95m
AMRNAmarin Corp. Plc -3.27%6.801.5%$36.10m

Company Profile

Verona Pharma Plc operates as a clinical-stage biopharmaceutical company, which engages in the development and commercialization of therapeutics for the treatment of respiratory diseases. Its lead product candidate, ensifentrine, has the potential to be the first therapy for the treatment of respiratory diseases that combines bronchodilator and anti-inflammatory activities in one compound. The company was founded by Michael J. A. Walker and Clive P. Page on February 24, 2005 and is headquartered in London, the United Kingdom.